alexa Henoch-Schonlein purpura | Singapore| PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Henoch-Schonlein Purpura

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Henoch-Schonlein purpura

    Henoch-Schonlein purpura: Henoch-Schonlein purpura (HSP) is a disease involving inflammation of small blood vessels. It most commonly occurs in children. The inflammation causes blood vessels in the skin, intestines, kidneys, and joints to start leaking.Symptoms: The main symptom is a rash with numerous small bruises, which have a raised appearance, over the legs or buttocks. 

  • Henoch-Schonlein purpura

    Pathophysiology: Henoch-Schonlein purpura is a small vessel vacuities in which complexes of immunoglobulin A (IgA) and complement component 3 (C3) are deposited on arterioles, capillaries, and venules. As with IgA nephropathy, serum levels of IgA are high in HSP and there are identical findings on renal biopsy.Diagnosis: A diagnosis of Henoch-Schonlein purpura is fairly easy to make if the classic rash, joint pain and gastrointestinal symptoms are present. If some of these signs and symptoms are missing, the following tests have to be done lab testes , biopsies, and imaging tests. 

  • Henoch-Schonlein purpura

     Treatment : Henoch-Schonlein purpura usually improves on its own within a month with no lasting ill effects. Bed rest, plenty of fluids and over-the-counter pain relievers may help.Causes: In Henoch-Schonlein purpura, some of the body's small blood vessels become inflamed, which can cause bleeding in the skin, joints, abdomen and kidneys. 

  • Henoch-Schonlein purpura

    Statistics : Ten patients (27%) progressed to end-stage renal failure (ESRF). Renal failure rates were highest in the first decade, with survival rate 72% at 5 years, 68% at 10 years and 46% at final review. Risk factors for ESRF were: proteinuria ?1 g/day during follow-up (RR 83.8, p = 0.0006); hypertension at presentation (RR = 53.3, p = 0.0045) and during follow-up (RR = 5.9, p = 0.05); renal impairment at presentation (RR 8.0, p = 0.0015); age <30 years (RR 7.6, p = 0.02); and male sex (RR = 6.0, p = 0.05). 


High Impact List of Articles

Conference Proceedings